Osaic Holdings
NTLA icon

Osaic Holdings’s Intellia Therapeutics NTLA Stock Holding History

Osaic Holdings’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35
Closed -$1.75K – 8123
2026
Q1 		$1.75K Buy
+35
New +$446 ﹤0.01% 7085
2022
Q1 		– Sell
-1
Closed -$1K – 7415
2021
Q4 		$1K Buy
+1
New +$125 ﹤0.01% 7219

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Osaic Holdings's NTLA Position: Q2 2026 in Review

Osaic Holdings increased its Intellia Therapeutics (NTLA) stake by 216% in Q2 2026, buying an estimated $605K and bringing the position to 63,242 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2939.

Osaic Holdings first reported a position in NTLA in Q1 2020 and has held it in 26 quarters since. The position peaked at $1.72M in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Osaic Holdings held 63,242 shares of Intellia Therapeutics worth $1.07M as of Q2 2026.
  • Osaic Holdings bought 43,257 Intellia Therapeutics shares in Q2 2026, an estimated $605K.
  • Intellia Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #2939 holding.
  • Osaic Holdings first reported a position in Intellia Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Intellia Therapeutics position peaked at $1.72M in Q2 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.